MKI67 and neoplasm: The role of the proliferation marker Ki67 in predicting the progression of AGASAC cases has not been clearly defined; however, studies so far have found no association between per cent of Ki67 immunolabelling within the primary tumour and metastatic lymph nodes with overall median survival time (MST) [17,30].